JP2017511815A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017511815A5 JP2017511815A5 JP2016570940A JP2016570940A JP2017511815A5 JP 2017511815 A5 JP2017511815 A5 JP 2017511815A5 JP 2016570940 A JP2016570940 A JP 2016570940A JP 2016570940 A JP2016570940 A JP 2016570940A JP 2017511815 A5 JP2017511815 A5 JP 2017511815A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- compound
- pharmaceutical composition
- disorder
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 32
- 239000008194 pharmaceutical composition Substances 0.000 claims 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 19
- 208000035475 disorder Diseases 0.000 claims 19
- 125000000753 cycloalkyl group Chemical group 0.000 claims 17
- 229910052736 halogen Inorganic materials 0.000 claims 15
- 150000002367 halogens Chemical class 0.000 claims 15
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 13
- 125000001424 substituent group Chemical group 0.000 claims 13
- 125000004438 haloalkoxy group Chemical group 0.000 claims 10
- 229910052739 hydrogen Inorganic materials 0.000 claims 10
- 239000001257 hydrogen Substances 0.000 claims 10
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 10
- 125000001188 haloalkyl group Chemical group 0.000 claims 9
- 125000005842 heteroatom Chemical group 0.000 claims 9
- 229910052760 oxygen Inorganic materials 0.000 claims 9
- 229910052717 sulfur Inorganic materials 0.000 claims 9
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 8
- -1 nitro, cyano, amino Chemical group 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 8
- 125000004093 cyano group Chemical group *C#N 0.000 claims 7
- 125000001072 heteroaryl group Chemical group 0.000 claims 7
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 7
- 125000003118 aryl group Chemical group 0.000 claims 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 5
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 4
- 208000000733 Paroxysmal Hemoglobinuria Diseases 0.000 claims 4
- 102100036050 Phosphatidylinositol N-acetylglucosaminyltransferase subunit A Human genes 0.000 claims 4
- 206010064930 age-related macular degeneration Diseases 0.000 claims 4
- 208000002780 macular degeneration Diseases 0.000 claims 4
- 201000003045 paroxysmal nocturnal hemoglobinuria Diseases 0.000 claims 4
- 125000000217 alkyl group Chemical group 0.000 claims 3
- 125000000623 heterocyclic group Chemical group 0.000 claims 3
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 3
- 125000002950 monocyclic group Chemical group 0.000 claims 3
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 2
- 101100240527 Caenorhabditis elegans nhr-22 gene Proteins 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- 208000004451 Membranoproliferative Glomerulonephritis Diseases 0.000 claims 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 2
- 201000007737 Retinal degeneration Diseases 0.000 claims 2
- 206010003246 arthritis Diseases 0.000 claims 2
- 125000002527 bicyclic carbocyclic group Chemical group 0.000 claims 2
- 208000030533 eye disease Diseases 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 125000004043 oxo group Chemical group O=* 0.000 claims 2
- 208000023504 respiratory system disease Diseases 0.000 claims 2
- 230000004258 retinal degeneration Effects 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 125000006413 ring segment Chemical group 0.000 claims 2
- 125000003320 C2-C6 alkenyloxy group Chemical group 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 102000003706 Complement factor D Human genes 0.000 claims 1
- 108090000059 Complement factor D Proteins 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000002619 bicyclic group Chemical group 0.000 claims 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims 1
- 229910052796 boron Inorganic materials 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 239000000460 chlorine Substances 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 150000002222 fluorine compounds Chemical group 0.000 claims 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- 125000005186 naphthyloxy group Chemical group C1(=CC=CC2=CC=CC=C12)O* 0.000 claims 1
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 125000003831 tetrazolyl group Chemical group 0.000 claims 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims 1
- 229920002554 vinyl polymer Polymers 0.000 claims 1
- 0 C*(C)C[n]1c(ccc(*)c2)c2c(*)c1 Chemical compound C*(C)C[n]1c(ccc(*)c2)c2c(*)c1 0.000 description 2
- PIBARDGJJAGJAJ-NQIIRXRSSA-N CC(c(c1c2)n[n](CC(N(C[C@@H](C3)F)[C@@H]3C(Nc3nc(Br)ccc3)=O)=O)c1ccc2-c1cnc(C)nc1)=O Chemical compound CC(c(c1c2)n[n](CC(N(C[C@@H](C3)F)[C@@H]3C(Nc3nc(Br)ccc3)=O)=O)c1ccc2-c1cnc(C)nc1)=O PIBARDGJJAGJAJ-NQIIRXRSSA-N 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461944189P | 2014-02-25 | 2014-02-25 | |
| US61/944,189 | 2014-02-25 | ||
| US201462022916P | 2014-07-10 | 2014-07-10 | |
| US62/022,916 | 2014-07-10 | ||
| US201462046783P | 2014-09-05 | 2014-09-05 | |
| US62/046,783 | 2014-09-05 | ||
| PCT/US2015/017593 WO2015130838A1 (en) | 2014-02-25 | 2015-02-25 | Aryl, heteroaryl, and heterocyclic compounds for treatment of complement mediated disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018164274A Division JP6688352B2 (ja) | 2014-02-25 | 2018-09-03 | 補体媒介障害の治療のためのアリール化合物、ヘテロアリール化合物及び複素環式化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017511815A JP2017511815A (ja) | 2017-04-27 |
| JP2017511815A5 true JP2017511815A5 (enExample) | 2017-11-24 |
| JP6400738B2 JP6400738B2 (ja) | 2018-10-03 |
Family
ID=53881572
Family Applications (9)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016570944A Active JP6537532B2 (ja) | 2014-02-25 | 2015-02-25 | 補体媒介障害の治療のための化合物 |
| JP2016570941A Pending JP2017508788A (ja) | 2014-02-25 | 2015-02-25 | 補体媒介障害の治療のためのエーテル化合物 |
| JP2016570940A Active JP6400738B2 (ja) | 2014-02-25 | 2015-02-25 | 補体媒介障害の治療のためのアリール化合物、ヘテロアリール化合物及び複素環式化合物 |
| JP2016570938A Pending JP2017506672A (ja) | 2014-02-25 | 2015-02-25 | 補体媒介性疾患の治療用アミノ化合物 |
| JP2016570937A Pending JP2017506269A (ja) | 2014-02-25 | 2015-02-25 | 補体媒介障害の治療のためのアミド化合物 |
| JP2016570942A Pending JP2017507184A (ja) | 2014-02-25 | 2015-02-25 | 補体媒介障害の治療のためのホスホネート化合物 |
| JP2018164274A Active JP6688352B2 (ja) | 2014-02-25 | 2018-09-03 | 補体媒介障害の治療のためのアリール化合物、ヘテロアリール化合物及び複素環式化合物 |
| JP2020060825A Active JP6948426B2 (ja) | 2014-02-25 | 2020-03-30 | 補体媒介障害の治療のためのアリール化合物、ヘテロアリール化合物及び複素環式化合物 |
| JP2021150181A Active JP7374967B2 (ja) | 2014-02-25 | 2021-09-15 | 補体媒介障害の治療のためのアリール化合物、ヘテロアリール化合物及び複素環式化合物 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016570944A Active JP6537532B2 (ja) | 2014-02-25 | 2015-02-25 | 補体媒介障害の治療のための化合物 |
| JP2016570941A Pending JP2017508788A (ja) | 2014-02-25 | 2015-02-25 | 補体媒介障害の治療のためのエーテル化合物 |
Family Applications After (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016570938A Pending JP2017506672A (ja) | 2014-02-25 | 2015-02-25 | 補体媒介性疾患の治療用アミノ化合物 |
| JP2016570937A Pending JP2017506269A (ja) | 2014-02-25 | 2015-02-25 | 補体媒介障害の治療のためのアミド化合物 |
| JP2016570942A Pending JP2017507184A (ja) | 2014-02-25 | 2015-02-25 | 補体媒介障害の治療のためのホスホネート化合物 |
| JP2018164274A Active JP6688352B2 (ja) | 2014-02-25 | 2018-09-03 | 補体媒介障害の治療のためのアリール化合物、ヘテロアリール化合物及び複素環式化合物 |
| JP2020060825A Active JP6948426B2 (ja) | 2014-02-25 | 2020-03-30 | 補体媒介障害の治療のためのアリール化合物、ヘテロアリール化合物及び複素環式化合物 |
| JP2021150181A Active JP7374967B2 (ja) | 2014-02-25 | 2021-09-15 | 補体媒介障害の治療のためのアリール化合物、ヘテロアリール化合物及び複素環式化合物 |
Country Status (30)
| Country | Link |
|---|---|
| US (33) | US9695205B2 (enExample) |
| EP (10) | EP3110419A4 (enExample) |
| JP (9) | JP6537532B2 (enExample) |
| KR (7) | KR20160116017A (enExample) |
| CN (8) | CN107073000A (enExample) |
| AP (5) | AP2016009437A0 (enExample) |
| AU (7) | AU2015223072A1 (enExample) |
| BR (1) | BR112016019526B1 (enExample) |
| CA (6) | CA2940769A1 (enExample) |
| CY (1) | CY1122550T1 (enExample) |
| DK (1) | DK3110418T3 (enExample) |
| EA (5) | EA035501B1 (enExample) |
| ES (2) | ES2771950T3 (enExample) |
| FI (1) | FIC20240030I1 (enExample) |
| FR (1) | FR24C1034I2 (enExample) |
| HR (2) | HRP20200182T1 (enExample) |
| HU (2) | HUE047295T2 (enExample) |
| IL (8) | IL301427B2 (enExample) |
| LT (3) | LT4129407T (enExample) |
| MX (6) | MX2016011037A (enExample) |
| NL (1) | NL301286I2 (enExample) |
| PL (1) | PL3110418T3 (enExample) |
| PT (1) | PT3110418T (enExample) |
| RS (2) | RS66541B1 (enExample) |
| RU (3) | RU2016137678A (enExample) |
| SA (1) | SA516371744B1 (enExample) |
| SI (1) | SI3110418T1 (enExample) |
| SM (1) | SMT202000046T1 (enExample) |
| WO (8) | WO2015130838A1 (enExample) |
| ZA (2) | ZA201605829B (enExample) |
Families Citing this family (89)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9695205B2 (en) | 2014-02-25 | 2017-07-04 | Achillion Pharmaceuticals, Inc. | Amide compounds for treatment of complement mediated disorders |
| WO2016138520A1 (en) | 2015-02-27 | 2016-09-01 | The Johns Hopkins University | Assay to diagnose and treat disorders of the alternative pathway of complement activation |
| AR105808A1 (es) | 2015-08-26 | 2017-11-08 | Achillion Pharmaceuticals Inc | Compuestos de amida para el tratamiento de trastornos médicos |
| WO2017035401A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amide compounds for treatment of immune and inflammatory disorders |
| EP3340983B1 (en) | 2015-08-26 | 2023-10-04 | Achillion Pharmaceuticals, Inc. | Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders |
| AR105809A1 (es) | 2015-08-26 | 2017-11-08 | Achillion Pharmaceuticals Inc | Compuestos para el tratamiento de trastornos médicos |
| WO2017035351A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amino compounds for treatment of medical disorders |
| US10385097B2 (en) | 2015-08-26 | 2019-08-20 | Achillion Pharmaceuticals, Inc. | Ether compounds for treatment of medical disorders |
| WO2017035405A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amino compounds for treatment of immune and inflammatory disorders |
| WO2017035408A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Compounds for treatment of immune and inflammatory disorders |
| WO2017035361A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Disubstituted compounds for the treatment of medical disorders |
| AR106018A1 (es) * | 2015-08-26 | 2017-12-06 | Achillion Pharmaceuticals Inc | Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos |
| US10000516B2 (en) | 2015-08-26 | 2018-06-19 | Achillion Pharmaceuticals, Inc. | Phosphonate compounds for treatment of medical disorders |
| WO2017070089A1 (en) | 2015-10-19 | 2017-04-27 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| ES2928856T3 (es) | 2015-11-19 | 2022-11-23 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
| CA3007922A1 (en) * | 2015-12-11 | 2017-06-15 | Lifesci Pharmaceuticals, Inc. | Therapeutic inhibitory compounds |
| WO2017106634A1 (en) | 2015-12-17 | 2017-06-22 | Incyte Corporation | N-phenyl-pyridine-2-carboxamide derivatives and their use as pd-1/pd-l1 protein/protein interaction modulators |
| TWI850624B (zh) | 2015-12-22 | 2024-08-01 | 美商英塞特公司 | 作為免疫調節劑之雜環化合物 |
| CA3011819A1 (en) | 2016-01-20 | 2017-07-27 | Vitrisa Therapeutics, Inc. | Compositions and methods for inhibiting factor d |
| TWI747873B (zh) | 2016-02-01 | 2021-12-01 | 美商百歐克斯製藥公司 | 苯并吡唑化合物及其類似物 |
| ES2906460T3 (es) | 2016-05-06 | 2022-04-18 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
| TW201808902A (zh) | 2016-05-26 | 2018-03-16 | 美商英塞特公司 | 作為免疫調節劑之雜環化合物 |
| PT3472167T (pt) | 2016-06-20 | 2022-11-11 | Incyte Corp | Compostos heterocíclicos como imunomoduladores |
| US20180016260A1 (en) | 2016-07-14 | 2018-01-18 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| WO2018015818A2 (en) * | 2016-07-15 | 2018-01-25 | Lifesci Pharmaceuticals, Inc. | Therapeutic inhibitory compounds |
| DE102016114392A1 (de) * | 2016-08-03 | 2018-02-08 | Eberhard Karls Universität Tübingen Medizinische Fakultät | Verbindung zur Behandlung einer mit einer Desregulierung des alternativen Komplementweges assoziierten Erkrankung |
| MA46045A (fr) | 2016-08-29 | 2021-04-28 | Incyte Corp | Composés hétérocycliques utilisés comme immunomodulateurs |
| US20180072718A1 (en) | 2016-09-09 | 2018-03-15 | Incyte Corporation | Pyrazolopyridine compounds and uses thereof |
| TW201811799A (zh) | 2016-09-09 | 2018-04-01 | 美商英塞特公司 | 吡唑并嘧啶化合物及其用途 |
| MA46191A (fr) | 2016-09-09 | 2021-04-21 | Incyte Corp | Dérivés de pyrazolopyridine comme modulateurs de hpk1 et leurs utilisations pour le traitement du cancer |
| EP3558973B1 (en) | 2016-12-22 | 2021-09-15 | Incyte Corporation | Pyridine derivatives as immunomodulators |
| JP7101678B2 (ja) | 2016-12-22 | 2022-07-15 | インサイト・コーポレイション | 免疫調節剤としての複素環式化合物 |
| RS63710B1 (sr) | 2016-12-22 | 2022-11-30 | Incyte Corp | Derivati tetrahidro imidazo[4,5-c] piridina kao induktori internalizacije pd-l1 |
| TW201835049A (zh) | 2016-12-22 | 2018-10-01 | 美商英塞特公司 | 作為免疫調節劑之雜環化合物 |
| US20180179201A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| WO2018136827A1 (en) | 2017-01-20 | 2018-07-26 | Vitrisa Therapeutics, Inc. | Stem-loop compositions and methods for inhibiting factor d |
| US20180228786A1 (en) | 2017-02-15 | 2018-08-16 | Incyte Corporation | Pyrazolopyridine compounds and uses thereof |
| JP7169979B2 (ja) * | 2017-02-27 | 2022-11-11 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 補体関連腎症および肝線維症の候補治療剤の治療有効性を評価する方法 |
| ES2933513T3 (es) | 2017-03-01 | 2023-02-09 | Achillion Pharmaceuticals Inc | Compuestos macrocíclicos para el tratamiento de trastornos médicos |
| PT3985002T (pt) * | 2017-03-01 | 2025-08-29 | Achillion Pharmaceuticals Inc | Compostos farmacêuticos de arilo, heteroarilo e heterocíclicos para tratamento de distúrbios médicos |
| WO2018160891A1 (en) * | 2017-03-01 | 2018-09-07 | Achillion Pharmaceutical, Inc. | Pharmaceutical compounds for treatment of medical disorders |
| WO2018229543A2 (en) * | 2017-06-14 | 2018-12-20 | Lifesci Pharmaceuticals, Inc. | Therapeutic inhibitory compounds |
| EP3661493A4 (en) * | 2017-08-02 | 2021-04-14 | Achillion Pharmaceuticals, Inc. | THERAPY PLANS FOR TREATMENT OF PAROXYSMALER NIGHTLY HEMOGLOBINURIA |
| US10722495B2 (en) | 2017-09-08 | 2020-07-28 | Incyte Corporation | Cyanoindazole compounds and uses thereof |
| KR101969521B1 (ko) * | 2017-10-26 | 2019-08-13 | 에스케이텔레콤 주식회사 | 사물인터넷용 단말과 모바일 단말의 접속을 관리하는 방법 및 이러한 방법을 수행하는 기지국 |
| US10745388B2 (en) | 2018-02-20 | 2020-08-18 | Incyte Corporation | Indazole compounds and uses thereof |
| MX2020008656A (es) | 2018-02-20 | 2020-12-09 | Incyte Corp | Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores de la cinasa de progenitores hematopoyeticos 1 (hpk1) para tratar el cancer. |
| US10752635B2 (en) | 2018-02-20 | 2020-08-25 | Incyte Corporation | Indazole compounds and uses thereof |
| RS66699B1 (sr) | 2018-03-30 | 2025-05-30 | Incyte Corp | Heterociklična jedinjenja kao imunomodulatori |
| TWI873092B (zh) | 2018-04-06 | 2025-02-21 | 美商百歐克斯製藥公司 | 取代的苯并呋喃、苯并吡咯、苯并噻吩及結構相關的補體抑制劑 |
| US11299473B2 (en) | 2018-04-13 | 2022-04-12 | Incyte Corporation | Benzimidazole and indole compounds and uses thereof |
| TW202425987A (zh) | 2018-05-11 | 2024-07-01 | 美商英塞特公司 | 作為免疫調節劑之雜環化合物 |
| MY209468A (en) | 2018-05-29 | 2025-07-10 | Omeros Corp | Masp-2 inhibitors and methods of use |
| EP3801499B1 (en) * | 2018-06-07 | 2024-02-28 | Disarm Therapeutics, Inc. | Inhibitors of sarm1 |
| US10899755B2 (en) | 2018-08-08 | 2021-01-26 | Incyte Corporation | Benzothiazole compounds and uses thereof |
| US20230022157A1 (en) | 2018-08-20 | 2023-01-26 | Achillion Pharmaceuticals, Inc. | Pharmaceutical compounds for the treatment of complement factor d medical disorders |
| MX2021002640A (es) * | 2018-09-06 | 2021-07-16 | Achillion Pharmaceuticals Inc | Formas morficas de los inhibidores del factor d del complemento. |
| JP7443375B2 (ja) | 2018-09-06 | 2024-03-05 | アキリオン ファーマシューティカルズ， インコーポレーテッド | 医学的障害の治療のための大環状化合物 |
| JP7399968B2 (ja) | 2018-09-25 | 2023-12-18 | インサイト・コーポレイション | Ａｌｋ２及び／またはｆｇｆｒ調節剤としてのピラゾロ［４，３－ｄ］ピリミジン化合物 |
| EP3856164B1 (en) * | 2018-09-25 | 2024-08-07 | Achillion Pharmaceuticals, Inc. | Morphic forms of complement factor d inhibitors |
| WO2020092183A1 (en) | 2018-11-01 | 2020-05-07 | Merck Sharp & Dohme Corp. | Novel substituted pyrazole compounds as indoleamine 2,3-dioxygenase inhibitors |
| WO2020112581A1 (en) * | 2018-11-28 | 2020-06-04 | Merck Sharp & Dohme Corp. | Novel substituted piperazine amide compounds as indoleamine 2, 3-dioxygenase (ido) inhibitors |
| WO2020109343A1 (en) | 2018-11-29 | 2020-06-04 | F. Hoffmann-La Roche Ag | Combination therapy for treatment of macular degeneration |
| US12239645B2 (en) | 2018-12-17 | 2025-03-04 | Achillion Pharmaceuticals, Inc. | Targeted dosing for the treatment of complement mediated disorders |
| KR20220004024A (ko) * | 2019-03-22 | 2022-01-11 | 아칠리온 파르마세우티칼스 인코포레이티드 | 보체 매개 장애의 치료를 위한 약제학적 조성물 |
| AU2020323532A1 (en) * | 2019-07-31 | 2022-03-03 | Biocryst Pharmaceuticals, Inc. | Dosing regimens for oral complement Factor D inhibitors |
| CN114450276A (zh) | 2019-08-06 | 2022-05-06 | 因赛特公司 | Hpk1抑制剂的固体形式 |
| TW202115059A (zh) | 2019-08-09 | 2021-04-16 | 美商英塞特公司 | Ｐｄ—１／ｐｄ—ｌ１抑制劑之鹽 |
| JP7559059B2 (ja) | 2019-09-30 | 2024-10-01 | インサイト・コーポレイション | 免疫調節剤としてのピリド［３，２－ｄ］ピリミジン化合物 |
| PH12022551136A1 (en) | 2019-11-11 | 2023-10-09 | Incyte Corp | Salts and crystalline forms of a pd-1/pd-l1 inhibitor |
| KR20220110530A (ko) | 2019-12-04 | 2022-08-08 | 오메로스 코포레이션 | Masp-2 억제자 및 사용 방법 |
| EP4069676A1 (en) * | 2019-12-04 | 2022-10-12 | Omeros Corporation | Masp-2 inhibitors and methods of use |
| EP4107166A4 (en) | 2020-02-20 | 2024-06-26 | Achillion Pharmaceuticals, Inc. | HETEROARYL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT FACTOR D-MEDIATED DISORDERS |
| US20210335448A1 (en) * | 2020-04-27 | 2021-10-28 | Advaita Corporation | Methods of identifying treatments using differentially expressed genes |
| CA3182156A1 (en) | 2020-05-08 | 2021-11-11 | Psilera Inc. | Novel compositions of matter and pharmaceutical compositions |
| CN113777302A (zh) * | 2020-06-09 | 2021-12-10 | 张曼 | 尿液补体因子d及其多肽片段在烧伤中的应用 |
| CN111704617B (zh) * | 2020-06-15 | 2022-08-23 | 嘉兴特科罗生物科技有限公司 | 一种小分子化合物 |
| JP7787164B2 (ja) * | 2020-09-23 | 2025-12-16 | アキリオン ファーマシューティカルズ， インコーポレーテッド | 補体媒介性障害の治療のための医薬化合物 |
| TW202233616A (zh) | 2020-11-06 | 2022-09-01 | 美商英塞特公司 | 用於製備ｐｄ－１／ｐｄ－ｌ１抑制劑以及其鹽及結晶形式之方法 |
| TW202233615A (zh) | 2020-11-06 | 2022-09-01 | 美商英塞特公司 | Ｐｄ—１／ｐｄ—ｌ１抑制劑之結晶形式 |
| US11780836B2 (en) | 2020-11-06 | 2023-10-10 | Incyte Corporation | Process of preparing a PD-1/PD-L1 inhibitor |
| US12378194B2 (en) | 2021-05-25 | 2025-08-05 | Atai Therapeutics, Inc. | N, n-dimethyltryptamine salts and crystalline salt forms |
| WO2023023227A1 (en) | 2021-08-20 | 2023-02-23 | Alexion Pharmaceuticals, Inc. | Methods for treating sickle cell disease or beta thalassemia using complement alternative pathway inhibitors |
| KR20240069793A (ko) * | 2021-09-30 | 2024-05-20 | 우한 크리에이터나 사이언스 앤드 테크놀로지 컴퍼니, 리미티드 | 보체 인자 d 억제제로서의 화합물, 이의 약학 조성물 및 용도 |
| WO2023158772A1 (en) | 2022-02-21 | 2023-08-24 | Teva Pharmaceuticals International Gmbh | Solid state forms of danicopan and process thereof |
| WO2024008121A1 (zh) * | 2022-07-06 | 2024-01-11 | 南京明德新药研发有限公司 | 二氟取代的氮杂双环化合物及其应用 |
| CA3201039A1 (en) * | 2023-03-13 | 2025-03-12 | Alexion Pharmaceuticals, Inc. | Formulations of danicopan and methods of use thereof |
| WO2025019800A1 (en) * | 2023-07-19 | 2025-01-23 | Atai Therapeutics, Inc. | Novel prodrugs and conjugates of dimethyltryptamine and methods of using the same |
| WO2026014456A1 (ja) * | 2024-07-10 | 2026-01-15 | 株式会社アークメディスン | 化合物、補体ｄ因子阻害剤、及び医薬組成物 |
Family Cites Families (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9206757D0 (en) | 1992-03-27 | 1992-05-13 | Ferring Bv | Novel peptide receptor ligands |
| US6074642A (en) | 1994-05-02 | 2000-06-13 | Alexion Pharmaceuticals, Inc. | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis |
| AU7808198A (en) | 1997-06-03 | 1998-12-21 | Biocryst Pharmaceuticals, Inc. | Novel compounds useful in the complement, coagulat and kallikrein pathways and method for their preparation |
| AU754716B2 (en) | 1998-03-26 | 2002-11-21 | Japan Tobacco Inc. | Amide derivatives and nociceptin antagonists |
| EP1112275B9 (en) | 1998-09-09 | 2004-03-10 | Metabasis Therapeutics, Inc. | Novel heteroaromatic inhibitors of fructose 1,6-bisphosphatase |
| WO2001017980A1 (en) | 1999-09-03 | 2001-03-15 | Ajinomoto Co., Inc. | Novel processes for preparing oxazepine derivatives |
| US7528165B2 (en) | 2001-12-13 | 2009-05-05 | National Health Research Institutes | Indole compounds |
| NZ537853A (en) | 2002-07-16 | 2007-02-23 | Amura Therapeutics Ltd | Inhibitors of cathepsin K and related cysteine protesases of the CA clan |
| US7632858B2 (en) | 2002-11-15 | 2009-12-15 | Bristol-Myers Squibb Company | Open chain prolyl urea-related modulators of androgen receptor function |
| AU2003902946A0 (en) | 2003-06-12 | 2003-06-26 | Fujisawa Pharmaceutical Co., Ltd. | Dpp-iv inhibitor |
| BRPI0506629A (pt) | 2004-02-10 | 2007-05-02 | Univ Colorado | inibição do fator b, a via alternativa do sistema complemento e métodos relacionados |
| ES2530056T3 (es) | 2004-03-24 | 2015-02-26 | Shire Orphan Therapies Gmbh | Nuevos compuestos para la inhibición de la angiogénesis y su uso |
| US7417063B2 (en) | 2004-04-13 | 2008-08-26 | Bristol-Myers Squibb Company | Bicyclic heterocycles useful as serine protease inhibitors |
| EP1814576A2 (en) | 2004-07-20 | 2007-08-08 | Critical Therapeutics, Inc. | Combination therapies of hmgb and complement inhibitors against inflammation |
| EP1981854B1 (en) * | 2005-12-14 | 2011-06-01 | Bristol-Myers Squibb Company | Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor xia inhibitors |
| EP2108642A1 (en) | 2006-10-17 | 2009-10-14 | Kyowa Hakko Kirin Co., Ltd. | Jak inhibitor |
| RU2470918C2 (ru) | 2007-01-15 | 2012-12-27 | Сантен Фармасьютикал Ко., Лтд. | НОВЫЕ ПРОИЗВОДНЫЕ ИНДОЛА, ОБЛАДАЮЩИЕ ИНГИБИРУЮЩЕЙ АКТИВНОСТЬЮ В ОТНОШЕНИИ IκB КИНАЗЫ β |
| WO2009091826A2 (en) | 2008-01-14 | 2009-07-23 | The Board Of Regents Of The University Of Texas System | Compositions and methods related to a human cd19-specific chimeric antigen receptor (h-car) |
| US9060981B2 (en) | 2009-10-16 | 2015-06-23 | Mochida Pharmaceutical Co., Ltd. | Marker associated with non-alcoholic steatohepatitis |
| NZ602777A (en) | 2010-04-16 | 2014-07-25 | Ac Immune Sa | Novel compounds for the treatment of diseases associated with amyloid or amyloid-like proteins |
| PE20140471A1 (es) * | 2011-01-04 | 2014-04-13 | Novartis Ag | Moduladores de la via del complemento y usos de los mismos |
| JP2014518223A (ja) | 2011-06-20 | 2014-07-28 | アルツハイマーズ・インスティテュート・オブ・アメリカ・インコーポレイテッド | 化合物とその治療用途 |
| EP3524258B1 (en) | 2011-06-22 | 2025-10-01 | Apellis Pharmaceuticals, Inc. | Methods of treating chronic disorders with complement inhibitors |
| NZ741873A (en) | 2012-05-03 | 2019-04-26 | Kala Pharmaceuticals Inc | Pharmaceutical nanoparticles showing improved mucosal transport |
| US9056874B2 (en) | 2012-05-04 | 2015-06-16 | Novartis Ag | Complement pathway modulators and uses thereof |
| US9579360B2 (en) | 2012-06-20 | 2017-02-28 | The Trustees Of The University Of Pennsylvania | Methods of treating or preventing periodontitis and diseases associated with periodontitis |
| EP2867229B1 (en) | 2012-06-28 | 2017-07-26 | Novartis AG | Pyrrolidine derivatives and their use as complement pathway modulators |
| JP6209605B2 (ja) | 2012-06-28 | 2017-10-04 | ノバルティス アーゲー | ピロリジン誘導体、および補体経路調節因子としてのその使用 |
| JP6214647B2 (ja) | 2012-06-28 | 2017-10-18 | ノバルティス アーゲー | 補体経路モジュレーターおよびその使用 |
| BR112014032734A2 (pt) | 2012-06-28 | 2017-06-27 | Novartis Ag | derivados de pirrolidina e seu uso como moduladores da série de reação de complemento |
| CN105121429B (zh) | 2012-06-28 | 2017-12-12 | 诺华股份有限公司 | 补体途径调节剂和其用途 |
| CN104619698B (zh) | 2012-06-28 | 2016-08-31 | 诺华股份有限公司 | 吡咯烷衍生物及其作为补体途径调节剂的用途 |
| ITMI20121156A1 (it) * | 2012-06-29 | 2013-12-30 | Consiglio Nazionale Ricerche | Metodo di elaborazione di immagini di tomografia a coerenza ottica |
| WO2014002059A1 (en) | 2012-06-29 | 2014-01-03 | Novartis Ag | CRYSTALLINE FORMS OF 1-(2-((1R,3S,5R)-3-(((R)-1-(3-chloro-2-fluorophenyl)ethyl)carbamoyl)-2-azabicyclo[3.1.0]hexan-2-yl)-2-oxoethyl)-1Hpyrazolo[3,4-c]pyridine-3-carboxamide |
| WO2014005150A1 (en) | 2012-06-29 | 2014-01-03 | Novartis Ag | Crystalline forms of l-(2-((lr,3s,5r)-3-( (2 -fluoro-3 - (trifluoromethoxy) phenyl) carbamoyl) - 2 -azabicycl o [3.1.0] hexan- 2 -yl) - 2 -oxoethyl) - 5 -methyl - 1h - pyrazolo [3, 4 -c] pyridine - 3 - carboxami de and salts thereof |
| CN104684910B (zh) | 2012-07-12 | 2016-10-12 | 诺华股份有限公司 | 补体途经调节剂及其用途 |
| MX2015002954A (es) | 2012-09-10 | 2015-06-05 | Hoffmann La Roche | Nuevas 6-aminoacido-heteroarilhidropirimidinas para el tratamiento y profilaxis de la infeccion del virus de la hepatitis b. |
| US9773428B2 (en) | 2012-12-11 | 2017-09-26 | Fluidity Software, Inc. | Computerized system and method for teaching, learning, and assessing step by step solutions to stem problems |
| CN108350086A (zh) | 2013-01-23 | 2018-07-31 | 南卡罗来纳医科大学研究发展基金会 | 基于天然抗体的靶向构建体及其用途 |
| JP2016169161A (ja) | 2013-07-19 | 2016-09-23 | 大日本住友製薬株式会社 | 新規イミダゾピリジン化合物 |
| US9695205B2 (en) | 2014-02-25 | 2017-07-04 | Achillion Pharmaceuticals, Inc. | Amide compounds for treatment of complement mediated disorders |
| US10385097B2 (en) | 2015-08-26 | 2019-08-20 | Achillion Pharmaceuticals, Inc. | Ether compounds for treatment of medical disorders |
| WO2017035418A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Disubstituted compounds for treatment of immune and inflammatory disorders |
| WO2017035408A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Compounds for treatment of immune and inflammatory disorders |
| AR105808A1 (es) | 2015-08-26 | 2017-11-08 | Achillion Pharmaceuticals Inc | Compuestos de amida para el tratamiento de trastornos médicos |
| AR106018A1 (es) | 2015-08-26 | 2017-12-06 | Achillion Pharmaceuticals Inc | Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos |
| WO2017035413A2 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Carbamate, ester, and ketone compounds for treatment of immune and inflammatory disorders |
| AR105809A1 (es) | 2015-08-26 | 2017-11-08 | Achillion Pharmaceuticals Inc | Compuestos para el tratamiento de trastornos médicos |
| WO2017035348A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Alkyne compounds for treatment of medical disorders |
| WO2017035351A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amino compounds for treatment of medical disorders |
| EP3340983B1 (en) | 2015-08-26 | 2023-10-04 | Achillion Pharmaceuticals, Inc. | Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders |
| WO2017035417A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Phosphonate compounds for treatment of immune and inflammatory disorders |
| WO2017035411A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Ether compounds for treatment of immune and inflammatory disorders |
| WO2017035352A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Carbamate, ester, and ketone compounds for treatment of medical disorders |
| WO2017035362A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Use of complement pathway inhibitor compounds to mitigate adoptive t-cell therapy associated adverse immune responses |
| WO2017035415A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Alkyne compounds for treatment of immune and inflammatory disorders |
| WO2017035405A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amino compounds for treatment of immune and inflammatory disorders |
| WO2017035401A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amide compounds for treatment of immune and inflammatory disorders |
| WO2017035361A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Disubstituted compounds for the treatment of medical disorders |
| US10000516B2 (en) | 2015-08-26 | 2018-06-19 | Achillion Pharmaceuticals, Inc. | Phosphonate compounds for treatment of medical disorders |
| CA3007922A1 (en) | 2015-12-11 | 2017-06-15 | Lifesci Pharmaceuticals, Inc. | Therapeutic inhibitory compounds |
| CA3011819A1 (en) | 2016-01-20 | 2017-07-27 | Vitrisa Therapeutics, Inc. | Compositions and methods for inhibiting factor d |
| PT3985002T (pt) | 2017-03-01 | 2025-08-29 | Achillion Pharmaceuticals Inc | Compostos farmacêuticos de arilo, heteroarilo e heterocíclicos para tratamento de distúrbios médicos |
| ES2933513T3 (es) | 2017-03-01 | 2023-02-09 | Achillion Pharmaceuticals Inc | Compuestos macrocíclicos para el tratamiento de trastornos médicos |
| WO2018160891A1 (en) | 2017-03-01 | 2018-09-07 | Achillion Pharmaceutical, Inc. | Pharmaceutical compounds for treatment of medical disorders |
-
2015
- 2015-02-25 US US14/631,233 patent/US9695205B2/en active Active
- 2015-02-25 JP JP2016570944A patent/JP6537532B2/ja active Active
- 2015-02-25 IL IL301427A patent/IL301427B2/en unknown
- 2015-02-25 AP AP2016009437A patent/AP2016009437A0/en unknown
- 2015-02-25 CA CA2940769A patent/CA2940769A1/en not_active Abandoned
- 2015-02-25 MX MX2016011037A patent/MX2016011037A/es unknown
- 2015-02-25 EP EP15756010.3A patent/EP3110419A4/en not_active Withdrawn
- 2015-02-25 CN CN201580010599.XA patent/CN107073000A/zh active Pending
- 2015-02-25 CN CN201580010603.2A patent/CN106413707A/zh active Pending
- 2015-02-25 KR KR1020167026158A patent/KR20160116017A/ko not_active Withdrawn
- 2015-02-25 CN CN201580010614.0A patent/CN106414427A/zh active Pending
- 2015-02-25 EP EP19206925.0A patent/EP3623367B1/en active Active
- 2015-02-25 US US14/631,440 patent/US9732103B2/en active Active
- 2015-02-25 EP EP15755233.2A patent/EP3110423A4/en not_active Withdrawn
- 2015-02-25 CN CN201580010604.7A patent/CN106456604B/zh active Active
- 2015-02-25 JP JP2016570941A patent/JP2017508788A/ja active Pending
- 2015-02-25 EA EA201691725A patent/EA035501B1/ru unknown
- 2015-02-25 EA EA201691730A patent/EA032690B1/ru not_active IP Right Cessation
- 2015-02-25 CN CN202011097580.2A patent/CN112250673A/zh active Pending
- 2015-02-25 WO PCT/US2015/017593 patent/WO2015130838A1/en not_active Ceased
- 2015-02-25 MX MX2016011035A patent/MX373962B/es active IP Right Grant
- 2015-02-25 EP EP15755617.6A patent/EP3110418B1/en active Active
- 2015-02-25 US US14/631,625 patent/US9796741B2/en active Active
- 2015-02-25 KR KR1020167026096A patent/KR102383714B1/ko active Active
- 2015-02-25 AP AP2016009434A patent/AP2016009434A0/en unknown
- 2015-02-25 WO PCT/US2015/017538 patent/WO2015130795A1/en not_active Ceased
- 2015-02-25 LT LTEP22193148.8T patent/LT4129407T/lt unknown
- 2015-02-25 RU RU2016137678A patent/RU2016137678A/ru unknown
- 2015-02-25 MX MX2016011036A patent/MX2016011036A/es unknown
- 2015-02-25 EP EP15755701.8A patent/EP3110806A4/en not_active Withdrawn
- 2015-02-25 CA CA2940777A patent/CA2940777A1/en active Pending
- 2015-02-25 RS RS20250190A patent/RS66541B1/sr unknown
- 2015-02-25 JP JP2016570940A patent/JP6400738B2/ja active Active
- 2015-02-25 WO PCT/US2015/017523 patent/WO2015130784A1/en not_active Ceased
- 2015-02-25 PL PL15755617T patent/PL3110418T3/pl unknown
- 2015-02-25 CA CA2940774A patent/CA2940774A1/en not_active Abandoned
- 2015-02-25 WO PCT/US2015/017597 patent/WO2015130842A2/en not_active Ceased
- 2015-02-25 MX MX2020004950A patent/MX387345B/es unknown
- 2015-02-25 RU RU2016137832A patent/RU2703995C2/ru active
- 2015-02-25 AP AP2016009436A patent/AP2016009436A0/en unknown
- 2015-02-25 AP AP2016009438A patent/AP2016009438A0/en unknown
- 2015-02-25 JP JP2016570938A patent/JP2017506672A/ja active Pending
- 2015-02-25 CA CA2940772A patent/CA2940772C/en active Active
- 2015-02-25 EA EA201691727A patent/EA201691727A1/ru unknown
- 2015-02-25 PT PT157556176T patent/PT3110418T/pt unknown
- 2015-02-25 US US14/631,785 patent/US9663543B2/en not_active Expired - Fee Related
- 2015-02-25 AU AU2015223072A patent/AU2015223072A1/en not_active Abandoned
- 2015-02-25 EP EP22193148.8A patent/EP4129407B1/en active Active
- 2015-02-25 DK DK15755617.6T patent/DK3110418T3/da active
- 2015-02-25 LT LTEP15755617.6T patent/LT3110418T/lt unknown
- 2015-02-25 AU AU2015223121A patent/AU2015223121A1/en not_active Abandoned
- 2015-02-25 KR KR1020167026171A patent/KR20160116018A/ko not_active Withdrawn
- 2015-02-25 US US14/631,312 patent/US9598446B2/en not_active Expired - Fee Related
- 2015-02-25 CA CA2940775A patent/CA2940775A1/en not_active Abandoned
- 2015-02-25 AU AU2015223068A patent/AU2015223068B2/en active Active
- 2015-02-25 KR KR1020167026303A patent/KR102366025B1/ko active Active
- 2015-02-25 AU AU2015223075A patent/AU2015223075A1/en not_active Abandoned
- 2015-02-25 RU RU2016137524A patent/RU2016137524A/ru unknown
- 2015-02-25 HR HRP20200182TT patent/HRP20200182T1/hr unknown
- 2015-02-25 HR HRP20250154TT patent/HRP20250154T1/hr unknown
- 2015-02-25 EP EP15755573.1A patent/EP3110805B1/en active Active
- 2015-02-25 EP EP15755090.6A patent/EP3110804A4/en not_active Withdrawn
- 2015-02-25 BR BR112016019526-4A patent/BR112016019526B1/pt active IP Right Grant
- 2015-02-25 KR KR1020167026134A patent/KR20160116016A/ko not_active Withdrawn
- 2015-02-25 JP JP2016570937A patent/JP2017506269A/ja active Pending
- 2015-02-25 US US14/631,090 patent/US9828396B2/en active Active
- 2015-02-25 EP EP15754619.3A patent/EP3110416A4/en not_active Withdrawn
- 2015-02-25 CN CN202010351035.5A patent/CN111437278A/zh active Pending
- 2015-02-25 KR KR1020167026308A patent/KR20160118368A/ko not_active Withdrawn
- 2015-02-25 KR KR1020227010934A patent/KR20220047666A/ko not_active Ceased
- 2015-02-25 EA EA201691731A patent/EA201691731A1/ru unknown
- 2015-02-25 US US14/630,959 patent/US9643986B2/en not_active Expired - Fee Related
- 2015-02-25 AP AP2016009435A patent/AP2016009435A0/en unknown
- 2015-02-25 AU AU2015223084A patent/AU2015223084B2/en not_active Ceased
- 2015-02-25 WO PCT/US2015/017554 patent/WO2015130806A1/en not_active Ceased
- 2015-02-25 EA EA201691728A patent/EA201691728A1/ru unknown
- 2015-02-25 ES ES15755617T patent/ES2771950T3/es active Active
- 2015-02-25 AU AU2015223132A patent/AU2015223132A1/en not_active Abandoned
- 2015-02-25 US US14/631,828 patent/US9758537B2/en active Active
- 2015-02-25 WO PCT/US2015/017609 patent/WO2015130854A1/en not_active Ceased
- 2015-02-25 ES ES19206925T patent/ES2933956T3/es active Active
- 2015-02-25 MX MX2016011034A patent/MX2016011034A/es unknown
- 2015-02-25 JP JP2016570942A patent/JP2017507184A/ja active Pending
- 2015-02-25 CN CN201580010598.5A patent/CN106458981B/zh active Active
- 2015-02-25 EP EP15754663.1A patent/EP3110417A4/en not_active Withdrawn
- 2015-02-25 WO PCT/US2015/017583 patent/WO2015130830A1/en not_active Ceased
- 2015-02-25 WO PCT/US2015/017600 patent/WO2015130845A1/en not_active Ceased
- 2015-02-25 CN CN201580010615.5A patent/CN106456605A/zh active Pending
- 2015-02-25 HU HUE15755617A patent/HUE047295T2/hu unknown
- 2015-02-25 MX MX2016011038A patent/MX2016011038A/es unknown
- 2015-02-25 CA CA2940645A patent/CA2940645A1/en not_active Abandoned
- 2015-02-25 SM SM20200046T patent/SMT202000046T1/it unknown
- 2015-02-25 US US14/631,683 patent/US9732104B2/en active Active
- 2015-02-25 RS RS20200115A patent/RS59854B1/sr unknown
- 2015-02-25 SI SI201531039T patent/SI3110418T1/sl unknown
-
2016
- 2016-08-22 ZA ZA2016/05829A patent/ZA201605829B/en unknown
- 2016-08-22 ZA ZA2016/05832A patent/ZA201605832B/en unknown
- 2016-08-24 US US15/245,872 patent/US20160362433A1/en not_active Abandoned
- 2016-08-24 IL IL247454A patent/IL247454A0/en unknown
- 2016-08-24 IL IL247453A patent/IL247453A0/en unknown
- 2016-08-24 US US15/246,049 patent/US20160361329A1/en not_active Abandoned
- 2016-08-24 US US15/245,712 patent/US10005802B2/en active Active
- 2016-08-24 IL IL24745016A patent/IL247450B/en active IP Right Grant
- 2016-08-24 US US15/245,945 patent/US20160362432A1/en not_active Abandoned
- 2016-08-24 US US15/245,788 patent/US20160362399A1/en not_active Abandoned
- 2016-08-24 IL IL247452A patent/IL247452B/en active IP Right Grant
- 2016-08-24 IL IL247449A patent/IL247449A0/en unknown
- 2016-08-25 SA SA516371744A patent/SA516371744B1/ar unknown
-
2017
- 2017-03-20 US US15/463,701 patent/US10189869B2/en active Active
- 2017-04-24 US US15/494,926 patent/US20170226142A1/en not_active Abandoned
- 2017-05-26 US US15/607,120 patent/US10100072B2/en active Active
- 2017-06-29 US US15/638,076 patent/US10428094B2/en active Active
- 2017-06-29 US US15/638,081 patent/US10370394B2/en active Active
- 2017-08-14 US US15/676,411 patent/US10106563B2/en active Active
- 2017-09-11 US US15/700,550 patent/US10087203B2/en active Active
- 2017-09-21 US US15/711,794 patent/US10081645B2/en active Active
- 2017-11-20 US US15/818,559 patent/US20180072762A1/en not_active Abandoned
-
2018
- 2018-06-12 US US16/006,520 patent/US20180291046A1/en not_active Abandoned
- 2018-06-12 US US16/006,476 patent/US20180298043A1/en not_active Abandoned
- 2018-06-12 US US16/006,533 patent/US20180291047A1/en not_active Abandoned
- 2018-09-03 JP JP2018164274A patent/JP6688352B2/ja active Active
- 2018-09-24 US US16/140,148 patent/US10253053B2/en active Active
- 2018-10-01 US US16/148,622 patent/US10428095B2/en active Active
- 2018-10-16 US US16/162,162 patent/US10301336B2/en active Active
- 2018-10-18 US US16/164,632 patent/US10550140B2/en active Active
-
2019
- 2019-01-14 US US16/246,832 patent/US10689409B2/en active Active
- 2019-02-14 US US16/276,139 patent/US10464956B2/en active Active
- 2019-10-03 IL IL269806A patent/IL269806B/en unknown
- 2019-11-01 US US16/672,114 patent/US12065459B2/en active Active
-
2020
- 2020-01-31 CY CY20201100084T patent/CY1122550T1/el unknown
- 2020-03-30 JP JP2020060825A patent/JP6948426B2/ja active Active
- 2020-10-28 AU AU2020260434A patent/AU2020260434B2/en active Active
-
2021
- 2021-07-25 IL IL285114A patent/IL285114B2/en unknown
- 2021-09-15 JP JP2021150181A patent/JP7374967B2/ja active Active
-
2024
- 2024-08-06 NL NL301286C patent/NL301286I2/nl unknown
- 2024-08-14 FR FR24C1034C patent/FR24C1034I2/fr active Active
- 2024-08-15 HU HUS2400030C patent/HUS2400030I1/hu unknown
- 2024-08-16 FI FIC20240030C patent/FIC20240030I1/fi unknown
-
2025
- 2025-04-08 LT LTPA2025514C patent/LTPA2025514I1/lt unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017511815A5 (enExample) | ||
| JP2017508789A5 (enExample) | ||
| JP2018526367A5 (enExample) | ||
| RU2016137524A (ru) | Амидные соединения для лечения опосредованных комплементом нарушений | |
| JP2019509276A5 (enExample) | ||
| JP2016515560A5 (enExample) | ||
| JP2013545816A5 (enExample) | ||
| JP2013545817A5 (enExample) | ||
| JP2017523169A5 (enExample) | ||
| JP2018520195A5 (enExample) | ||
| JP2017512833A5 (enExample) | ||
| JP2013545818A5 (enExample) | ||
| JP2014501766A5 (enExample) | ||
| RU2012156940A (ru) | Лекарственные средства, индуцирующие апоптоз, для лечения рака и иммунных и аутоиммунных заболеваний | |
| JP2016537382A5 (enExample) | ||
| JP2016540742A5 (enExample) | ||
| RU2015106434A (ru) | Производные типа азаиндазола или диазаиндазола для лечения боли | |
| JP2016518434A5 (enExample) | ||
| JP2015522650A5 (enExample) | ||
| JP2013532652A5 (enExample) | ||
| RU2013126041A (ru) | Пиразолопиридины и пиразолопиридины и их применение в качестве ингибиторов tyk2 | |
| JP2016518328A5 (enExample) | ||
| JP2016523270A5 (enExample) | ||
| JP2016525136A5 (enExample) | ||
| JP2018511647A5 (enExample) |